HOME / Notice / News / EN
NKCL Bio Group announced that it had recently acquired a patent for a stimulant composition for rapid testing of natural killer cell activity and a test method using the same. Ph.D. Shin Dong-hyeok of NKCL Bio Group said, “Normally, NK cells in our body are inactive, but they are activated and respo...
NKCL Bio Group Inc. won the ‘2023 Customer Love Brand Grand Prize’ in the immune care platform category. |Growing into a global top bio company in the K-Bio field through immune care platform services On May 16th, NKCL Bio Group Inc., a bio company that researches and develops NK immune cell therap...
[2023 Customer Love Brand Award] Anti-aging solution ‘Just Ten Minutes’ is very popular NKCL Bio Group’s RK-NK100 anti-aging solution won the grand prize in the immune care platform category at the ‘2023 Customer Love Brand Awards’. The company holds patents and original technology for medium ad...
Acquired US patent for NK cell culture technology of NKCL Bio Group NKCL Bio Group (Chairman Shin Dong-hwa) announced that it had obtained a U.S. patent for NK cell culture technology. Recently, NKCL Bio Group successfully completed pre-clinical trials on the company's NK cell therapy pipeline for li...
[China-ROK (Changchun) International Cooperation Demonstration Zone Project, spurs the construction of a medical complex] A delegation from the 'China-ROK (Changchun) International Cooperation Demonstration Zone' (hereafter referred to as Changchun Demonstration Zone), an international industrial coo...